About Mannose-P-dolichol utilization defect 1 protein
Mannose-P-dolichol utilization defect 1 protein (MPDU1) is a protein
from Homo sapiens identified by UniProt accession
O75352, 247 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | Mannose-P-dolichol utilization defect 1 protein |
|---|
| UniProt accession | O75352 |
|---|
| Gene | MPDU1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 247 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (61)
Diseases linked to this target (Open Targets).
- MPDU1-congenital disorder of glycosylation · score 0.78
- SRD5A3-congenital disorder of glycosylation · score 0.55
- congenital disorder of glycosylation type I · score 0.53
- congenital disorder of glycosylation · score 0.51
- Seizure · score 0.37
- genetic disorder · score 0.33
- sex hormone-binding globulin measurement · score 0.28
- testosterone measurement · score 0.21
- cortical thickness · score 0.20
- platelet component distribution width · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75352-F1 | alphafold | PREDICTED | 88.74 | — |
Amino-acid sequence (247 residues)
MAAEADGPLK RLLVPILLPE KCYDQLFVQW DLLHVPCLKI LLSKGLGLGI VAGSLLVKLP QVFKILGAKS AEGLSLQSVM LELVALTGTM VYSITNNFPF SSWGEALFLM LQTITICFLV MHYRGQTVKG VAFLACYGLV LLVLLSPLTP LTVVTLLQAS NVPAVVVGRL LQAATNYHNG HTGQLSAITV FLLFGGSLAR IFTSIQETGD PLMAGTFVVS SLCNGLIAAQ LLFYWNAKPP HKQKKAQ
Explore Mannose-P-dolichol utilization defect 1 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets